Zentalis Pharmaceuticals (ZNTL) executive compensation, 2026 proxy

Julie Eastland, President and Chief Executive Officer, was paid $1.3M in 2025, down 84% from $8.2M the year before.

Filed
April 30, 2026
Annual meeting
June 16, 2026
Pay year
2025
Named executives
5
CEO total pay
$1.3M-84% vs prior year
CEO pay in equity
12%$156,747 in awards
CEO Salary
$700,0002025 base salary
CEO Non-Equity Incentive
$441,0002025 annual bonus earned
CMO Salary
$530,000For Ingmar Bruns
New CLO Option Awards
$391,752For James Bucher

How Eastland was paid

$1.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary54%Stock awards8%Option awards4%Non-equity incentive34%All other compensation0%

Named executive officers

ExecutiveTotal
Julie EastlandPresident and Chief Executive Officer$1,300,731
Ingmar Bruns, M.D.Chief Medical Officer$869,843
James BucherChief Legal Officer and Corporate Secretary$659,973
Andrea PaulFormer Chief Legal Officer and Corporate Secretary$2,988,669
Mark Lackner, Ph.D.Former Chief Scientific Officer$1,229,349

What changed and why

  • $1.3MCEO Julie Eastland earned total compensation of $1,300,731 for fiscal year 2025.
  • $8.2MCEO total compensation decreased significantly compared to the prior year total of $8,188,909.
  • $441KNon-equity incentive plan compensation for the CEO was $441,000 for 2025.
  • $50,000James Bucher joined as Chief Legal Officer with a signing bonus of $50,000.
  • $3MFormer executive Andrea Paul received total compensation of $2,988,669 including separation payments.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.